Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

ESMO open·2025

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

ESMO open·2022

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

ESMO open·2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

ESMO open·2021

Stroke in the Young: Incidence, 30-Day Case Fatality Rates, and Risk Factors Over Time in a Population-Based Study.

Neurology·2026

Long-Term Risk of Dementia After TIA: A Population-Wide Matched Cohort Study.

Neurology·2026

Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.

Neurology·2026

Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus: Insights From the ICTAL Registry.

Neurology·2026

Diagnosis, Treatment, and Prognosis of Cerebral Venous Thrombosis.

Neurology·2026

Vascular Imaging Features and Time-Specific Recurrence Risk After Craniocervical Artery Dissection.

Neurology·2026

Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.

Molecular neurodegeneration advances·2026

Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up.

Frontiers in immunology·2026

Immune checkpoint blockade reshapes drug-associated toxicity: a pharmacovigilance atlas of drug-ICI interactions.

medRxiv : the preprint server for health sciences·2026

Predicting Neoantigen Immunogenicity from In Vivo Immune Editing.

bioRxiv : the preprint server for biology·2026

Cross-species spatial profiling links progranulin to an immune suppressive niche in brain metastasis.

bioRxiv : the preprint server for biology·2026

Incidentally detected bilateral sub-internal limiting membrane hemorrhages in typical hemolytic uremic syndrome: a case report.

Childhood kidney diseases·2026

Related Experiment Videos

Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin

Related Concept Videos

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

Stroke in the Young: Incidence, 30-Day Case Fatality Rates, and Risk Factors Over Time in a Population-Based Study.

Long-Term Risk of Dementia After TIA: A Population-Wide Matched Cohort Study.

Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.

Diagnostic Yield and Therapeutic Impact of Etiologic Investigations After Status Epilepticus: Insights From the ICTAL Registry.

Diagnosis, Treatment, and Prognosis of Cerebral Venous Thrombosis.

Vascular Imaging Features and Time-Specific Recurrence Risk After Craniocervical Artery Dissection.

Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.

Long-term outcomes of eltrombopag plus cyclosporine A in eltrombopag-exposed patients with glucocorticoid-resistant or -dependent primary immune thrombocytopenia: a prospective, multicenter, single-arm, phase II study with extended follow-up.

Immune checkpoint blockade reshapes drug-associated toxicity: a pharmacovigilance atlas of drug-ICI interactions.

Predicting Neoantigen Immunogenicity from In Vivo Immune Editing.

Cross-species spatial profiling links progranulin to an immune suppressive niche in brain metastasis.

Incidentally detected bilateral sub-internal limiting membrane hemorrhages in typical hemolytic uremic syndrome: a case report.

Related Experiment Videos

Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin

Related Concept Videos

Related Articles